Balyasny Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.7M	Buy	+85,026	New	+$2.32M	0.01%	1652
2025 Q4	–	Sell	-11,632	Closed	-$301K	–	3152
2025 Q3	$301K	Buy	+11,632	New	+$270K	﹤0.01%	2576
2024 Q4	–	Sell	-86,573	Closed	-$2.94M	–	2813
2024 Q3	$2.94M	Buy	+86,573	New	+$3.3M	0.01%	1500
2024 Q2	–	Sell	-64,769	Closed	-$2.72M	–	2639
2024 Q1	$2.72M	Buy	64,769 +40,650	+169%	+$1.67M	0.01%	1449
2023 Q4	$957K	Sell	24,119 -3,296	-12%	-$96.9K	﹤0.01%	1707
2023 Q3	$754K	Buy	+27,415	New	+$859K	﹤0.01%	1636
2022 Q2	–	Sell	-61,240	Closed	-$2.09M	–	2814
2022 Q1	$2.09M	Buy	61,240 +53,878	+732%	+$1.72M	0.01%	1333
2021 Q4	$284K	Buy	+7,362	New	+$321K	﹤0.01%	1756
2018 Q2	–	Sell	-5,187	Closed	-$181K	–	1818
2018 Q1	$181K	Buy	5,187 +3,147	+154%	+$122K	﹤0.01%	1774
2017 Q4	$87K	Sell	2,040 -1,053	-34%	-$45.1K	﹤0.01%	1984
2017 Q3	$133K	Buy	+3,093	New	+$116K	﹤0.01%	1754
2015 Q3	–	Sell	-3,720	Closed	-$1.41M	–	1178
2015 Q2	$1.41M	Buy	+3,720	New	+$1.48M	0.01%	771
2013 Q3	–	Sell	-18,333	Closed	-$4.29M	–	588
2013 Q2	$4.29M	Buy	+18,333	New	+$3.61M	0.1%	321